Editorial policy

What Veritide does not do

• We do not sell, supply, hold stock of or dispatch any compound. Nothing is bought from Veritide.
• We do not tell anyone to buy, take or administer anything, and we publish no dosing or usage instructions.
• We do not present any compound as a medicine, a treatment or a health product. Every compound covered here is unlicensed in the UK.
• We do not provide medical advice, diagnosis or treatment guidance.

The rules every page follows

• Findings are reported in the third person and the past tense, attributed to the study or journal that published them. We do not write in a way that reads as encouragement, endorsement or recommendation.
• We publish no dosing amounts, administration routes, preparation-for-use instructions, schedules, cycling or combination guidance — on any page, in any context.
• Where a research material is listed, it is labelled as a listing, kept visually separate from the summary of the research, and disclosed as an affiliate link. It is never described as a medicine or a treatment.
• Commercial links have no influence on what a summary says. A compound with a listing is not written up more favourably than one without.
• Every compound profile carries a regulatory-status line stating that the compound is not an MHRA-licensed medicine and is not approved for human or animal use.
• Sources are cited so a reader can check the primary literature rather than take our summary on trust.
• Where the published record is thin, contested or limited to animal models, we say so in the article rather than smoothing it over.

How articles are written

Each Research Library entry summarises published work on a peptide or peptide class: proposed mechanism of action, study design, the population studied, what the investigators reported, and the limitations they themselves stated. Compound Profiles are reference pages, kept factual and deliberately dull — what a compound is, how it is proposed to act, where the evidence currently stands, and its regulatory status in plain terms.

We prioritise peer-reviewed primary literature and official regulatory publications. Preprints, conference abstracts and manufacturer communications are labelled as such when cited. Where a claim circulates widely without published support, we say that no published support exists.

Corrections

If a summary misreads a paper, cites the wrong study, or has been overtaken by newer work, we want to know. Corrections are made on the page itself rather than quietly. Contact the editorial desk.

How Veritide is funded, and what that means

Veritide is funded by affiliate links. Where a compound we write about is listed by a third-party UK laboratory supplier, we may include a link to that listing, and we may earn a commission if a reader buys through it. The price a reader pays is unaffected.

Those links are always labelled as listings and separated from the research summary, and they never change what a summary says. Materials listed are sold for laboratory research use only: they are not licensed medicines, are not approved for human or animal use, and Veritide provides no dosing, administration or preparation guidance anywhere on this site.